Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: Therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus

Current Opinion in Virology

Volumn 9, Issue , 2014, Pages 1-7

  Deval, Jerome ^a   Symons, Julian A ^a   Beigelman, Leo ^a  

^a Alios BioPharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 5B; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; RNA POLYMERASE; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT; DNA DIRECTED RNA POLYMERASE; ENZYME INHIBITOR; NUCLEOSIDE; NUCLEOTIDE; URIDINE PHOSPHATE;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; DRUG TARGETING; HEPATITIS C VIRUS; NONHUMAN; VIRUS INHIBITION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; HUMAN; RNA VIRUS;

ANTIVIRAL AGENTS; DNA-DIRECTED RNA POLYMERASES; ENZYME INHIBITORS; HUMANS; NUCLEOSIDES; NUCLEOTIDES; RNA VIRUSES; RNA, VIRAL; URIDINE MONOPHOSPHATE;

EID: 84907935404     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2014.08.004     Document Type: Review

References (65)

1. D. Moradpour, F. Penin, and C.M. Rice Replication of hepatitis C virus Nat Rev Microbiol 5 2007 453 463
2. D.M. Jensen A new era of hepatitis C therapy begins N Engl J Med 364 2011 1272 1274
3. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, and M. Diago Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
4. J. Deval, and M. Huber Hepatitis C Virus and its Inhibitors: The Polymerase as a Target for Nucleoside and Nucleotide Analogs. Cancer-causing Viruses and Their Inhibitors 2014 41 84 Chapter 3
5. C.A. Lesburg, M.B. Cable, E. Ferrari, Z. Hong, and A.F. Mannarino Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat Struct Biol 6 1999 937 943
6. H. Ago, T. Adachi, A. Yoshida, M. Yamamoto, and N. Habuka Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus Structure 7 1999 1417 1426
7. S. Bressanelli, L. Tomei, A. Roussel, I. Incitti, and R.L. Vitale Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus Proc Natl Acad Sci U S A 96 1999 13034 13039
8. C. Caillet-Saguy, P.C. Simister, and S. Bressanelli An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors J Mol Biol 414 2011 370 384
9. S. Chinnaswamy, I. Yarbrough, S. Palaninathan, C.T. Kumar, and V. Vijayaraghavan A locking mechanism regulates RNA synthesis and host protein interaction by the hepatitis C virus polymerase J Biol Chem 283 2008 20535 20546
10. N. Scrima, C. Caillet-Saguy, M. Ventura, D. Harrus, and T. Astier-Gin Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405 J Virol 86 2012 7107 7117
11. Z. Hong, C.E. Cameron, M.P. Walker, C. Castro, and N. Yao A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase Virology 285 2001 6 11
12. D. Maag, C. Castro, Z. Hong, and C.E. Cameron Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin J Biol Chem 276 2001 46094 46098
13. C.T. Ranjith-Kumar, L. Gutshall, R.T. Sarisky, and C.C. Kao Multiple interactions within the hepatitis C virus RNA polymerase repress primer-dependent RNA synthesis J Mol Biol 330 2003 675 685
14. R.T. Mosley, T.E. Edwards, E. Murakami, A.M. Lam, and R.L. Grice Structure of hepatitis C virus polymerase in complex with primer-template RNA J Virol 86 2012 6503 6511
15. D.F. Zamyatkin, F. Parra, J.M. Alonso, D.A. Harki, and B.R. Peterson Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase J Biol Chem 283 2008 7705 7712
16. Z. Jin, V. Leveque, H. Ma, K.A. Johnson, and K. Klumpp Assembly, purification, and pre-steady-state kinetic analysis of active RNA-dependent RNA polymerase elongation complex J Biol Chem 287 2012 10674 10683
17. M.H. Powdrill, E.P. Tchesnokov, R.A. Kozak, R.S. Russell, and R. Martin Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance Proc Natl Acad Sci U S A 108 2011 20509 20513
18. E. Walton, F.W. Holly, G.E. Boxer, and R.F. Nutt 3′-Deoxynucleosides. IV. Pyrimidine 3′-deoxynucleosides J Org Chem 31 1966 1163 1169
19. L.N. Beigelman, B.S. Ermolinsky, G.V. Gurskaya, E.N. Tsapkina, and M. Karpeisky A new synthesis of 2′-C-methylnucleosides starting from d-ribose Nucleic Acids Symp Ser 1987 41 44
20. L.P. Savochkina, T.V. Sviriaeva, L.N. Beigel'man, N. Padiukova, and D.A. Kuznetsov Substrate properties of C′-methylnucleoside triphosphates in a reaction of RNA synthesis catalyzed by Escherichia coli RNA-polymerase Mol Biol (Mosk) 23 1989 1700 1710
21. V.E. Buckwold, B.E. Beer, and R.O. Donis Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents Antiviral Res 60 2003 1 15
22. Carroll SS, LaFemina R, Hall DL, Himmelberger AL, Kuo LC, et al.: Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase. Patent number WO/2002/057425; 2002.
23. Sommadossi JP, La Colla P: Methods and compositions for treating hepatitis C virus. Patent number WO/2001/090121; 2001.
24. Sommadossi JP, La Colla P: Methods and compositions for treating flaviviruses and pestiviruses. Patent number WO/2001/092282; 2001.
25. D.N. Standring, R. Lanford, T. Wright, R.T. Chung, and V. Bichko NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee J Hepatol 38 2003 3
26. F. Poordad, E.J. Lawitz, N. Gitlin, M. Rodriguez-Torres, and T. Box Efficacy and safety of valopicitabine in combination with pegylated interferon-alpha (pegIFN) and ribavirin (RBV) in patients with chronic hepatitis C Hepatology 46 2007 866A
27. S.S. Carroll, J.E. Tomassini, M. Bosserman, K. Getty, and M.W. Stahlhut Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs J Biol Chem 278 2003 11979 11984
28. D.B. Olsen, A.B. Eldrup, L. Bartholomew, B. Bhat, and M.R. Bosserman A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties Antimicrob Agents Chemother 48 2004 3944 3953
29. S.S. Carroll, S. Ludmerer, L. Handt, K. Koeplinger, and N.R. Zhang Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees Antimicrob Agents Chemother 53 2009 926 934
30. H. Dutartre, C. Bussetta, J. Boretto, and B. Canard General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues Antimicrob Agents Chemother 50 2006 4161 4169
31. S.W. Ludmerer, D.J. Graham, E. Boots, E.M. Murray, and A. Simcoe Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay Antimicrob Agents Chemother 49 2005 2059 2069
32. G. Migliaccio, J.E. Tomassini, S.S. Carroll, L. Tomei, and S. Altamura Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro J Biol Chem 278 2003 49164 49170
33. H. Maag, R.M. Rydzewski, M.J. McRoberts, D. Crawford-Ruth, and J.P. Verheyden Synthesis and anti-HIV activity of 4′-azido- and 4′-methoxynucleosides J Med Chem 35 1992 1440 1451
34. K. Klumpp, V. Leveque, S. Le Pogam, H. Ma, and W.R. Jiang The novel nucleoside analog R1479 (4′-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture J Biol Chem 281 2006 3793 3799
35. S. Le Pogam, W.R. Jiang, V. Leveque, S. Rajyaguru, and H. Ma In vitro selected Con1 subgenomic replicons resistant to 2′-C-methyl-cytidine or to R1479 show lack of cross resistance Virology 351 2006 349 359
36. S.K. Roberts, G. Cooksley, G.J. Dore, R. Robson, and D. Shaw Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C Hepatology 48 2008 398 406
37. D.R. Nelson, S. Zeuzem, P. Andreone, P. Ferenci, and R. Herring Balapiravir plus peginterferon alfa-2a (40 kD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients Ann Hepatol 11 2012 15 31
38. K. Klumpp, G. Kalayanov, H. Ma, S. Le Pogam, and V. Leveque 2′-Deoxy-4′-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2′-alpha-hydroxyl groups J Biol Chem 283 2008 2167 2175
39. C. McGuigan, M.R. Kelleher, P. Perrone, S. Mulready, and G. Luoni The application of phosphoramidate ProTide technology to the potent anti-HCV compound 4′-azidocytidine (R1479) Bioorg Med Chem Lett 19 2009 4250 4254
40. D.B. Smith, G. Kalayanov, C. Sund, A. Winqvist, and T. Maltseva The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4′-azidocytidine against hepatitis C virus replication: the discovery of 4′-azido-2′-deoxy-2′-fluorocytidine and 4′-azido-2′-dideoxy-2′,2′-difluorocytidine J Med Chem 52 2009 2971 2978
41. D.B. Smith, J.A. Martin, K. Klumpp, S.J. Baker, and P.A. Blomgren Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: the discovery of R1479 Bioorg Med Chem Lett 17 2007 2570 2576
42. J.J. Arnold, S.D. Sharma, J.Y. Feng, A.S. Ray, and E.D. Smidansky Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides PLoS Pathog 8 2012 e1003030
43. L.J. Stuyver, T.R. McBrayer, T. Whitaker, P.M. Tharnish, and M. Ramesh Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2′-deoxy-2′-fluorocytidine Antimicrob Agents Chemother 48 2004 651 654
44. L.J. Stuyver, T.R. McBrayer, P.M. Tharnish, J. Clark, and L. Hollecker Inhibition of hepatitis C replicon RNA synthesis by beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication Antiviral Chem Chemother 17 2006 79 87
45. H. Ma, W.R. Jiang, N. Robledo, V. Leveque, and S. Ali Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species J Biol Chem 282 2007 29812 29820
46. E. Murakami, C. Niu, H. Bao, H.M. Micolochick Steuer, and T Whitaker The mechanism of action of beta-d-2′-deoxy-2′-fluoro-2′-C-methylcytidine involves a second metabolic pathway leading to beta-d-2′-deoxy-2′-fluoro-2′-C-methyluridine 5′-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase Antimicrob Agents Chemother 52 2008 458 464
47. P.A. Furman, A.M. Lam, and E. Murakami Nucleoside analog inhibitors of hepatitis C viral replication: recent advances, challenges and trends Future Med Chem 1 2009 1429 1452
48. M.J. Sofia, D. Bao, W. Chang, J. Du, and D. Nagarathnam Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J Med Chem 53 2010 7202 7218
49. A. Fung, Z. Jin, N. Dyatkina, G. Wang, and L. Beigelman Efficiency of incorporation and chain termination determines the inhibition potency of 2′-modified nucleotide analogs against HCV polymerase Antimicrob Agents Chemother 58 7 2014 3636 3645 10.1128/AAC.02666-14
50. E. De Clercq Current race in the development of DAAs (direct-acting antivirals) against HCV Biochem Pharmacol 89 2014 441 452
51. M.J. Sofia, W. Chang, P.A. Furman, R.T. Mosley, and B.S. Ross Nucleoside, nucleotide, and non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA-polymerase J Med Chem 55 2012 2481 2531
52. C. Chapron, R. Glen, M. La Colla, B.A. Mayes, and J.F. McCarville Synthesis of 2′-O,4′-C-alkylene-bridged ribonucleosides and their evaluation as inhibitors of HCV NS5B polymerase Bioorg Med Chem Lett 24 2014 2699 2702
53. Girijavallabhan V, Njoroge FG, Bogen S, Verma V, Bennett F, et al.: 2′-Substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases. Patent number WO/2012/142085; 2012.
54. E.V. Koonin The phylogeny of RNA-dependent RNA polymerases of positive-strand RNA viruses J Gen Virol 72 Pt 9 1991 2197 2206
55. A.J. Te Velthuis Common and unique features of viral RNA-dependent polymerases Cell Mol Life Sci 2014 [Epub ahead of print]
56. S. Benzaria, D. Bardiot, T. Bouisset, C. Counor, and C. Rabeson 2′-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication Antiviral Chem Chemother 18 2007 225 242
57. J.G. Julander, A.K. Jha, J.A. Choi, K.H. Jung, and D.F. Smee Efficacy of 2′-C-methylcytidine against yellow fever virus in cell culture and in a hamster model Antiviral Res 86 2010 261 267
58. M. Flint, L.K. McMullan, K.A. Dodd, B.H. Bird, and M.L. Khristova Inhibitors of the tick-borne, hemorrhagic fever-associated flaviviruses Antimicrob Agents Chemother 58 2014 3206 3216
59. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, and R. Cunha Inhibition of norovirus replication by the nucleoside analogue 2′-C-methylcytidine Biochem Biophys Res Commun 427 2012 796 800
60. J. Rocha-Pereira, D. Jochmans, Y. Debing, E. Verbeken, and M.S. Nascimento The viral polymerase inhibitor 2′-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model J Virol 87 2013 11798 11805
61. D.J. Lefebvre, A.R. De Vleeschauwer, N. Goris, D. Kollanur, and A. Billiet Proof of concept for the inhibition of foot-and-mouth disease virus replication by the anti-viral drug 2′-C-methylcytidine in severe combined immunodeficient mice Transbound Emerg Dis 2013 10.1111/tbed.12069
62. D.R. Latour, A. Jekle, H. Javanbakht, R. Henningsen, and P. Gee Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2′-ethynyl-7-deaza-adenosine triphosphate Antiviral Res 87 2010 213 222
63. Z. Yin, Y.L. Chen, W. Schul, Q.Y. Wang, and F. Gu An adenosine nucleoside inhibitor of dengue virus Proc Natl Acad Sci U S A 106 2009 20435 20439
64. N.M. Nguyen, C.N. Tran, L.K. Phung, K.T. Duong, and A. Huynh Hle A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients J Infect Dis 207 2013 1442 1450
65. C. McGuigan, K. Madela, M. Aljarah, C. Bourdin, and M. Arrica Phosphorodiamidates as a promising new phosphate prodrug motif for antiviral drug discovery: application to anti-HCV agents J Med Chem 54 2011 8632 8645